Publication | Open Access

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Pioneer 9Diabetes ManagementDiabetesPharmacologyClinical TrialsType 2Oral Semaglutide MonotherapyTreatment OptionPharmacotherapyDiabetes MellitusMedicineTreatment Development